Extended Data Fig. 5: Impact of complex II or direct purine synthesis inhibition on metabolite isotope tracing from 13C6-glucose or 15N1-glutamine. | Nature Metabolism

Extended Data Fig. 5: Impact of complex II or direct purine synthesis inhibition on metabolite isotope tracing from 13C6-glucose or 15N1-glutamine.

From: Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia

Extended Data Fig. 5: Impact of complex II or direct purine synthesis inhibition on metabolite isotope tracing from 13C6-glucose or 15N1-glutamine.

a) Effect of Complex II inhibition on 13C6-glucose-derived glutamate isotope abundance. b) Effect of Complex II inhibition on 13C6-glucose-derived glutamine isotope abundance. c-e) Effect of LTX on the incorporation of 15N1-glutamine into de novo purines (c) IMP, (d) adenylosuccinate and (e) AMP. f-l) Effect of either Complex II inhibition (TTFA) or LTX on 15N1-glutamine derived nitrogen into pyrimidines. Abbreviations: UTP, uridine triphosphate; CMP, cytidine monophosphate; CTP, cytidine triphosphate. m) Effect of Complex II inhibition on the fractional content of m + 5 citrate derived from 13C5-glutamine. All data are shown as mean ± s.e.m. of n = 3 independent experiments. P values were calculated using unpaired, two-tailed Student’s t-tests (a-e, m) or a one-way ANOVA with Tukey’s post-hoc test (f-l). For metabolites with multiple isotopes, the P values are reported for the total abundance.

Source Data

Back to article page